TxCell announces preclinical efficacy results for Col-Treg in autoimmune uveitis
9 September 2015 | By Victoria White
In vivo administration of Col-Treg in the model of autoimmune uveitis significantly inhibited clinical symptoms, retinal tissue lesions as well as ocular proinflammatory cell infiltration...